公开(公告)号：US20150211064A1

公开(公告)日：2015-07-30

申请号：US14114276

申请日：2012-06-06

申请人： Stefan Meuer ,  Thomas Geise ,  Christian Jacobi ,  Stefan Haag ,  Juergen Roemisch

发明人： Stefan Meuer ,  Thomas Geise ,  Christian Jacobi ,  Stefan Haag ,  Juergen Roemisch

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/156

摘要： A method for determining the likelihood of response of an individual, suffering from a disease, towards immunoglobulin therapy has the steps of providing a sample containing B- and T-lymphocytes, natural killer cells, invariant T-cells and monocytes of the individual; genotyping of at least one of the polynucleotides of an ADAMTS9-Intron; a KLHDC8A-Intron or of a flanking region of the CD14 gene, and awarding the value of 1 for the homozygous Single Nucleotide Polymorphism combinations, which suggests that the blood sample stems from a person which will not respond to immunoglobulin treatment, while awarding the value of 0 for SNP not meeting that criteria, which suggests that the blood sample stems from a person which will respond to immunoglobulin treatment.

摘要翻译： 确定患有疾病的个体对免疫球蛋白治疗的反应可能性的方法具有以下步骤：提供含有个体的B和T淋巴细胞，天然杀伤细胞，不变T细胞和单核细胞的样品; 至少一种ADAMTS9-内含子的多核苷酸的基因分型; KLHDC8A-内含子或CD14基因的侧翼区域，并且为纯合的单核苷酸多态性组合赋予1值，这表明血液样品源于不对免疫球蛋白治疗反应的人，同时赋予该值 为0的SNP不符合该标准，这表明血液样本来源于将对免疫球蛋白治疗作出反应的人。

公开(公告)号：US20100330568A1

公开(公告)日：2010-12-30

申请号：US12735313

申请日：2009-01-09

申请人： Stefan Meuer ,  Thomas Giese ,  Christian Jacobi ,  Jürgen Römisch ,  Stefan Haag

发明人： Stefan Meuer ,  Thomas Giese ,  Christian Jacobi ,  Jürgen Römisch ,  Stefan Haag

IPC分类号： C12Q1/68 ,  G01N33/68 ,  C12Q1/02

CPC分类号： G01N33/6854 ,  G01N33/5047

摘要： A method of determining a patient's susceptibility for NK cell modulation by immunoglobulins in response to a treatment of a disease or prophylaxis of a disease with immunoglobulins wherein a modulation of natural killer cells caused by said immunoglobulins is determined.

摘要翻译： 确定患者对免疫球蛋白响应于疾病治疗或用免疫球蛋白预防疾病的NK细胞调节的敏感性的方法，其中确定由所述免疫球蛋白引起的天然杀伤细胞的调节。